18 completed, 15 recruiting, 8 active not recruiting, 5 terminated. 40 Phase 2, 15 Phase 1, 4 Not applicable, 1 Early Phase 1.
Follow Adenoid Cystic Carcinoma: new trials by email Literature Review of Adenoid Cystic Carcinoma trials Research Report on Adenoid Cystic Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma Stereotactic body radiotherapy (SBRT) - Adenoid Cystic Carcinoma, Oligometastatic | Phase 2 | Not yet recruiting | All India Institute of Medical Sciences | 90 | 2026-12-20 | 2026-09-28 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-27 | 2026-10-22 |
| Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma Anlotinib + Epirubicin - Adenoid Cystic Carcinoma | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 76 | 2026-06-01 | 2026-06-01 |
| Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study Surgery - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Recruiting | Eye & ENT Hospital of Fudan University | 70 | 2026-06-01 | 2026-06-17 | |
| SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma Postoperative Radiotherapy, Observation - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Not yet recruiting | Eye & ENT Hospital of Fudan University | 200 | 2026-05-01 | 2026-05-12 | |
| Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) P-Sam - Adenoid Cystic Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 28 | 2026-04-29 | 2026-09-21 |
| A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma Becotatug Vedotin - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 40 | 2026-04-28 | 2026-07-28 |
| Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study Epirubicin (E) - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 100 | 2026-01-20 | 2026-05-12 |
| A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma Enfortumab Vedotin - Adenoid Cystic Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 34 | 2025-03-31 | 2026-10-01 |
| A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers Ivonescimab - Salivary Gland Cancer, Advanced Salivary Gland Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 35 | 2025-02-26 | 2026-10-21 |
| 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma 177Lu-PNT2002 - Adenoid Cystic Carcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2025-02-10 | 2026-01-22 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma HG146 - Adenoid Cystic Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | HitGen Inc. | 140 | 2024-12-13 | 2026-09-21 |
| Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) RGT-61159, lenvatinib - Adenoid Cystic Carcinoma, Colorectal Cancer | Phase 1 | Active not recruiting | Rgenta Therapeutics Inc | 105 | 2024-08-19 | 2026-09-17 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial Lutetium (177Lu) vipivotide tetraxetan - Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Maria Sklodowska-Curie National Research Institute of Oncology | 2024-01-01 | 2025-02-10 | |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma REM-422 - Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | Remix Therapeutics | 125 | 2023-12-20 | 2026-06-24 |
| CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC CB-103, Abemaciclib, Lenvatinib - Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | Michael J. Dennis, MD | 32 | 2023-06-01 | 2026-09-09 |
| A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors Emi-Le - Triple Negative Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Day One Biopharmaceuticals, Inc. | 360 | 2022-08-15 | 2026-06-29 |
Showing 20 of 56. Sign in to see all of them.
Carcinoma, Adenoid Cystic (56) · Salivary Gland Neoplasms (13) · Neoplasm Metastasis (6) · Colorectal Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Cholangiocarcinoma (3) · Fallopian Tube Neoplasms (3) · Gallbladder Neoplasms (3) · Head and Neck Neoplasms (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Recurrence (3) · Small Cell Lung Carcinoma (3) · Carcinoma (2)
Adenocarcinoma (56) · Neoplasms, Glandular and Epithelial (56) · Neoplasms (55) · Neoplasms by Histologic Type (55) · Carcinoma (54) · Neoplasms by Site (22) · Mouth Diseases (14) · Stomatognathic Diseases (14) · Head and Neck Neoplasms (13) · Mouth Neoplasms (13) · Salivary Gland Diseases (13) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Pathological Conditions, Signs and Symptoms (9) · Gastrointestinal Diseases (8)
pembrolizumab (7) · lenvatinib (4) · apatinib (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (2) · Carboplatin (2) · Epirubicin (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Radiosurgery (2) · Specimen Handling (2) · Surgical Procedures, Operative (2) · 177Lu-EB-PSMA-617 (1) · Axitinib (1) · BMS-906024 (1)
Eye & ENT Hospital of Fudan University (5) · Memorial Sloan Kettering Cancer Center (5) · Dana-Farber Cancer Institute (4) · M.D. Anderson Cancer Center (3) · Ayala Pharmaceuticals, Inc, (2) · Heidelberg University (2) · National Cancer Institute (NCI) (2) · Radboud University Medical Center (2) · Seoul National University Hospital (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Actuate Therapeutics Inc. (1) · All India Institute of Medical Sciences (1) · Cellestia Biotech AG (1) · Day One Biopharmaceuticals, Inc. (1) · Elevar Therapeutics (1)
United States (35) · China (9) · Canada (4) · Germany (4) · South Korea (4) · France (3) · Netherlands (3) · Australia (2) · Spain (2) · United Kingdom (2) · Brazil (1) · Guam (1) · Israel (1) · Poland (1) · Puerto Rico (1)
Alan Ho, MD, PhD (4) · Glenn J Hanna, MD (2) · Renata Ferrarotto, MD (2) · Alan L. Ho, MD, PhD (1) · Ana Kiess, MD, PhD (1) · Annie W Chan, MD (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Athanassios E Argiris, MD (1) · Camila MV Moniz, Doctor (1) · Carla ML van Herpen, MD, PhD (1) · Charalampos Floudas, M.D. (1) · Chenping Zhang, M.D. (1) · Do-Youn Oh, MD,PhD (1) · Elena Garalda, MD, PhD (1)
PMID 16757203, PMID 37097003, PMID 17960615, PMID 21612974, PMID 31463986, PMID 32629365, PMID 41089828, PMID 12112535, PMID 17761983, PMID 21320355, PMID 23747147, PMID 24033920, PMID 25362970, PMID 25456010, PMID 28551643, PMID 30447126, PMID 31586664, PMID 31650066, PMID 31969335, PMID 32781104, PMID 33362722, PMID 33882143, PMID 33995600, PMID 34266402, PMID 34380663, PMID 34503735, PMID 34716198, PMID 34927307, PMID 35984529, PMID 36734294, PMID 37294948, PMID 37643133, PMID 37703531, PMID 38118249, PMID 38243705, PMID 38358334, PMID 38539566, PMID 39067873, PMID 39097677, PMID 39343510, PMID 39417692, PMID 39563886, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40979299, PMID 41672597, PMID 41892875, PMID 41995270
2023 (1), P01CA021239 (1), R44CA250824 (1), U10CA180888 (1)